MX2018015067A - Solucion inyectable a ph 7 que comprende por lo menos una insulina basal cuyo pi esta comprendido entre 5.8 y 8.5, una insulina prandial y/o una hormona gastrointestinal y un co-poliamino acido que porta cargas de carboxilatos y de radicales hidrofobicos. - Google Patents
Solucion inyectable a ph 7 que comprende por lo menos una insulina basal cuyo pi esta comprendido entre 5.8 y 8.5, una insulina prandial y/o una hormona gastrointestinal y un co-poliamino acido que porta cargas de carboxilatos y de radicales hidrofobicos.Info
- Publication number
- MX2018015067A MX2018015067A MX2018015067A MX2018015067A MX2018015067A MX 2018015067 A MX2018015067 A MX 2018015067A MX 2018015067 A MX2018015067 A MX 2018015067A MX 2018015067 A MX2018015067 A MX 2018015067A MX 2018015067 A MX2018015067 A MX 2018015067A
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- acid bearing
- injectable solution
- carboxylate charges
- gastrointestinal hormone
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 8
- 102000004877 Insulin Human genes 0.000 title abstract 4
- 108090001061 Insulin Proteins 0.000 title abstract 4
- 229940125396 insulin Drugs 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 2
- 150000007942 carboxylates Chemical class 0.000 title abstract 2
- 239000003629 gastrointestinal hormone Substances 0.000 title abstract 2
- 230000002209 hydrophobic effect Effects 0.000 title abstract 2
- 229940102223 injectable solution Drugs 0.000 title 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con composiciones estables físicamente en la forma de una solución acuosa inyectable, cuyo pH es de 6.0 a 8.0, que comprende por lo menos: a) una insulina basal cuyo punto isoeléctrico (pI) es de 5.8 a 8.5, b) una hormona de insulina prandial o gastrointestinal y c) un co-poliamino ácido que porta cargas de carboxilato y por lo menos un radical hidrofóbico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1655222A FR3052072A1 (fr) | 2016-06-07 | 2016-06-07 | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| PCT/EP2017/063886 WO2017211916A1 (fr) | 2016-06-07 | 2017-06-07 | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, une insuline prandiale et/ou une hormone gastrointestinale, et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015067A true MX2018015067A (es) | 2019-05-09 |
Family
ID=57348773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015068A MX2018015068A (es) | 2016-06-07 | 2017-06-07 | Solucion inyectable a ph 7 que comprende por lo menos una insulina basal cuyo pi esta comprendido entre 5.8 y 8.5 y co-poliamino acido que porta cargas de carboxilatos y radicales hidrofobicos. |
| MX2018015067A MX2018015067A (es) | 2016-06-07 | 2017-06-07 | Solucion inyectable a ph 7 que comprende por lo menos una insulina basal cuyo pi esta comprendido entre 5.8 y 8.5, una insulina prandial y/o una hormona gastrointestinal y un co-poliamino acido que porta cargas de carboxilatos y de radicales hidrofobicos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015068A MX2018015068A (es) | 2016-06-07 | 2017-06-07 | Solucion inyectable a ph 7 que comprende por lo menos una insulina basal cuyo pi esta comprendido entre 5.8 y 8.5 y co-poliamino acido que porta cargas de carboxilatos y radicales hidrofobicos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10383920B2 (es) |
| EP (2) | EP3463292B1 (es) |
| JP (1) | JP2019517555A (es) |
| CN (2) | CN109640953B (es) |
| BR (2) | BR112018075140A2 (es) |
| EA (2) | EA039333B1 (es) |
| FR (1) | FR3052072A1 (es) |
| MX (2) | MX2018015068A (es) |
| PH (1) | PH12018502558B1 (es) |
| SA (2) | SA518400588B1 (es) |
| SG (2) | SG11201810937WA (es) |
| WO (2) | WO2017211916A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3070264A1 (fr) * | 2017-08-24 | 2019-03-01 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| FR3083089A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| KR20200106891A (ko) | 2017-12-07 | 2020-09-15 | 아도시아 | pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액 |
| FR3083086A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| IL275148B2 (en) | 2017-12-07 | 2025-02-01 | Adocia | An injectable solution with a pH of 7 comprising at least one basic insulin with a PI between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals. |
| WO2019110773A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| IL275146B2 (en) | 2017-12-07 | 2025-01-01 | Adocia | Preparations in the form of an aqueous solution for injection comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid |
| WO2019110797A1 (fr) * | 2017-12-07 | 2019-06-13 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| WO2019115411A1 (fr) * | 2017-12-07 | 2019-06-20 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide |
| BR112020011479A2 (pt) | 2017-12-07 | 2020-11-17 | Adocia | composições na forma de uma solução aquosa injetável caracterizada pelo fato de que compreende amilina, um agonista do receptor de amilina ou um análogo de amilina e um co-poliaminoácido |
| FR3067247A1 (fr) * | 2018-06-07 | 2018-12-14 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide |
| WO2019243628A1 (fr) * | 2018-06-22 | 2019-12-26 | Adocia | Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal |
| FR3084586B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes |
| FR3084585B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes |
| US20200179489A1 (en) * | 2018-12-07 | 2020-06-11 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol |
| WO2020115334A1 (fr) * | 2018-12-07 | 2020-06-11 | Adocia | Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable |
| WO2020245470A1 (fr) | 2019-06-07 | 2020-12-10 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985001890A1 (fr) | 1983-10-26 | 1985-05-09 | Kanebo, Ltd. | Agent emulsifiant proteique, son procede de preparation et preparation cosmetique emulsifiee le contenant |
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| FR2801226B1 (fr) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
| EP1545460A4 (en) | 2001-12-20 | 2005-11-16 | Lilly Co Eli | INSULIN MOLECULE WITH TEMPORARY EFFECT |
| FR2840614B1 (fr) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
| CA2518776A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| FR2862535B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques |
| FR2915683B1 (fr) * | 2007-05-03 | 2009-08-07 | Flamel Technologies Sa | Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif |
| CN103889442B (zh) * | 2011-08-10 | 2016-12-28 | 阿道恰公司 | 至少一种基础胰岛素的可注射溶液 |
| FR2985429B1 (fr) | 2012-01-09 | 2016-07-29 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle |
| CN113730555A (zh) * | 2012-01-09 | 2021-12-03 | 阿道恰公司 | Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液 |
| FR3001896B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise |
| FR3001895B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes |
-
2016
- 2016-06-07 FR FR1655222A patent/FR3052072A1/fr not_active Withdrawn
-
2017
- 2017-06-07 SG SG11201810937WA patent/SG11201810937WA/en unknown
- 2017-06-07 EA EA201892736A patent/EA039333B1/ru unknown
- 2017-06-07 US US15/616,128 patent/US10383920B2/en active Active
- 2017-06-07 US US15/616,470 patent/US10548952B2/en active Active
- 2017-06-07 CN CN201780047889.0A patent/CN109640953B/zh active Active
- 2017-06-07 BR BR112018075140-5A patent/BR112018075140A2/pt not_active Application Discontinuation
- 2017-06-07 SG SG11201810935SA patent/SG11201810935SA/en unknown
- 2017-06-07 CN CN201780035320.2A patent/CN109379888B/zh active Active
- 2017-06-07 EP EP17727906.4A patent/EP3463292B1/fr active Active
- 2017-06-07 WO PCT/EP2017/063886 patent/WO2017211916A1/fr not_active Ceased
- 2017-06-07 PH PH1/2018/502558A patent/PH12018502558B1/en unknown
- 2017-06-07 EA EA201892737A patent/EA039363B1/ru unknown
- 2017-06-07 MX MX2018015068A patent/MX2018015068A/es unknown
- 2017-06-07 MX MX2018015067A patent/MX2018015067A/es unknown
- 2017-06-07 EP EP17727910.6A patent/EP3463293B1/fr active Active
- 2017-06-07 BR BR112018075151-0A patent/BR112018075151A2/pt not_active Application Discontinuation
- 2017-06-07 JP JP2018564355A patent/JP2019517555A/ja active Pending
- 2017-06-07 WO PCT/EP2017/063865 patent/WO2017211903A1/fr not_active Ceased
-
2018
- 2018-12-04 SA SA518400588A patent/SA518400588B1/ar unknown
- 2018-12-05 SA SA518400596A patent/SA518400596B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170348396A1 (en) | 2017-12-07 |
| US10548952B2 (en) | 2020-02-04 |
| CN109640953A (zh) | 2019-04-16 |
| CN109379888A (zh) | 2019-02-22 |
| EA039333B1 (ru) | 2022-01-14 |
| EA039363B1 (ru) | 2022-01-18 |
| SG11201810937WA (en) | 2019-01-30 |
| WO2017211916A1 (fr) | 2017-12-14 |
| EA201892737A1 (ru) | 2019-05-31 |
| BR112018075151A2 (pt) | 2019-03-26 |
| FR3052072A1 (fr) | 2017-12-08 |
| PH12018502558A1 (en) | 2019-10-14 |
| CN109640953B (zh) | 2021-10-29 |
| EP3463293A1 (fr) | 2019-04-10 |
| JP2019517555A (ja) | 2019-06-24 |
| WO2017211903A1 (fr) | 2017-12-14 |
| BR112018075140A2 (pt) | 2019-03-26 |
| EP3463292B1 (fr) | 2020-08-05 |
| MX2018015068A (es) | 2019-05-09 |
| PH12018502558B1 (en) | 2024-02-02 |
| SA518400588B1 (ar) | 2022-03-07 |
| EA201892736A1 (ru) | 2019-05-31 |
| SA518400596B1 (ar) | 2022-03-16 |
| US20170348423A1 (en) | 2017-12-07 |
| US10383920B2 (en) | 2019-08-20 |
| EP3463293B1 (fr) | 2021-05-12 |
| SG11201810935SA (en) | 2019-01-30 |
| EP3463292A1 (fr) | 2019-04-10 |
| CN109379888B (zh) | 2021-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502558B1 (en) | Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals | |
| MX2025009746A (es) | Solucion inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoacido con cargas de carboxilato y radicales hidrofobicos | |
| MX2018015070A (es) | Composiciones en forma de solucion acuosa inyectable, que comprende glucagon humano y un co-poliaminoacido injertado en el extremo. | |
| WO2019110797A8 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide | |
| PH12020550828A1 (en) | Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid | |
| SG11202005322RA (en) | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals | |
| MY182507A (en) | Aqueous ophthalmic solution | |
| IL272141A (en) | Preparations in the form of an aqueous solution for injection containing at least human insulin A21G and suppressing glucagon activity with a meal | |
| FR3001896B1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise | |
| MX2025008231A (es) | Composiciones en forma de una solucion acuosa inyectable que comprende amilina, un receptor agonista de amilina o un analogo de amilina y un copoliaminoacido | |
| SG11202005320VA (en) | Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid | |
| MX2016004328A (es) | Inmunopotenciador. | |
| EA202091374A1 (ru) | РАСТВОР ДЛЯ ИНЪЕКЦИЙ С pH 7, СОДЕРЖАЩИЙ ПО МЕНЬШЕЙ МЕРЕ ОДИН БАЗАЛЬНЫЙ ИНСУЛИН С pI МЕЖДУ 5,8 И 8,5 И СОПОЛИАМИНОКИСЛОТУ, НЕСУЩУЮ КАРБОКСИЛАТНЫЕ ЗАРЯДЫ И ГИДРОФОБНЫЕ РАДИКАЛЫ | |
| FR3074681B1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| MX2020006670A (es) | Composicion acuosa que comprende acido 2-(dimetil-1h-pirazol-1-il) succinico y amoniaco. | |
| EA202091387A1 (ru) | Композиции в форме инъецируемого водного раствора, содержащие человеческий глюкагон и сополиаминокислоту | |
| SG11201804902UA (en) | A composition for improving memory, learning ability, and cognitive ability | |
| FR3074683B1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide | |
| FR3074422B1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| PL410126A1 (pl) | Sposób otrzymywania zawiesiny nanocząstek chitozan-srebro i nanokompozytu chitozan-srebro |